Navigation Links
AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008
Date:2/10/2009

Patients filled 2.7 million prescriptions through AZ&Me(TM) Prescription Savings Programs

WILMINGTON, Del., Feb. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it provided $612.6 million in savings to 440,541 patients in the United States last year through its AZ&Me(TM) Prescription Savings programs.

Patients filled 2.7 million prescriptions through the programs in 2008.

"AstraZeneca is committed to helping patients who are facing health and financial challenges," said Rich Fante, President of AstraZeneca US. "Our prescription savings programs provide support for patients who might otherwise go without the medicines they need."

AstraZeneca provides free or low-cost medicines to patients through its AZ&Me(TM) Prescription Savings programs in three ways:

  • Individuals: AstraZeneca provides free medicines to qualifying individuals without prescription drug coverage who make up to $30,000 per year and families of four with $60,000 annual household income.

  • Part D beneficiaries: AstraZeneca provides low-cost medicines for qualifying Medicare Part D patients who make up to $30,000 per year or couples who make up to $40,000 per year.

  • Healthcare facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program connects patients to the medicines they need at the same time and place they receive their treatment.

AstraZeneca has offered prescription savings programs side by side with its medicines for three decades and offers one of the industry's most generous programs.

In 2009, AstraZeneca will continue to reach patients who need help through a variety of channels, including community health centers, our product advertisements, and health care professionals and advocates, who are the leading source of information about our programs, according to an AstraZeneca survey. The company also participates in the Partnership for Prescription Assistance, a multi-company program.

Patients can learn more about the AZ&Me Prescription Savings program at www.azandme.com or by calling 1-800-AZandMe.

A podcast related to this news release can be found here.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit http://www.astrazeneca-us.com./


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
2. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
3. AstraZenecas Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
4. AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva
5. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
6. AstraZenecas Purplepill.com Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008
7. AstraZeneca Recognized as One of Working Mother Magazines 100 Best Companies
8. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
9. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
10. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
11. A Drug That Carries a Lower Risk of Weight Gain Than AstraZenecas Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President ... the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. ... in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, EarQ ... the unique opportunity to learn more about Signia’s technology and the successful business and ... is our priority to see practices succeed in this highly competitive industry,” said Ed ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing company in ... 35 years. Maintaining core values of exceptional customer service, quality work at reasonable rates, ... leading name in San Diego plumbing, and other services including heating & air conditioning ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
Breaking Medicine Technology: